(EN) EKBG – Lp(a)

A revolutionary drug for lowering Lp(a) levels in patients at cardiovascular risk or who have experienced a cardiovascular event.

A Phase 3 clinical trial to investigate the effect of muvalaplin on reducing serious adverse cardiovascular events in adults with elevated Lp(a) levels who have a history of atherosclerotic cardiovascular events or are at risk of a first atherosclerotic event.

Book
examination